Understanding the Growing Use of GLP-1 Drugs in the U.S.: How Many People Are On GLP-1 Drugs?

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The prescription landscape for GLP-1 receptor agonist medications has shifted dramatically over the past three years, with usage rates climbing across multiple patient demographics in the U.S. Recent industry data suggests that approximately 9-15 million Americans have filled at least one GLP-1 prescription, reflecting a fundamental change in how weight loss and metabolic disease are being treated in clinical practice. This surge reflects both improved clinical evidence and growing accessibility through compounded formulations.

How Many Americans Currently Use GLP-1 Medications

Current market analysis indicates that between 9 and 15 million Americans have filled a GLP-1 prescription at some point, making these medications among the most widely prescribed pharmaceutical agents in recent history. The rapid adoption began accelerating in 2022 and has continued climbing steadily through 2024, driven largely by increased insurance coverage, celebrity endorsements, and word-of-mouth success stories from individuals achieving significant weight reduction. Compounded GLP-1 options have further expanded access by eliminating insurance gatekeeping and reducing financial barriers to entry.

Demographic breakdown shows that patients aged 40-65 represent the largest segment of GLP-1 users, though prescription rates are rising notably in younger adults seeking preventive metabolic support. Women constitute approximately 60-65% of the user base, reflecting both higher obesity prevalence in female populations and greater treatment-seeking behavior among women. Type 2 diabetes patients represent roughly 30-40% of total GLP-1 prescriptions, while the remainder are patients pursuing weight loss and cardiovascular risk reduction without diabetes diagnosis.

Growth Trends in GLP-1 Prescription Rates Across the Nation

Prescription growth rates for GLP-1 medications have exceeded 100% year-over-year in multiple calendar periods, outpacing nearly every other medication class tracked by pharmacy benefit managers and compounding pharmacies. Urban and suburban markets have led adoption initially, though rural prescription rates are now accelerating as telehealth-based prescribing platforms reduce geographic barriers. State-level data reveals highest penetration in the Northeast and West Coast, with Southern and Midwest markets showing steeper growth curves as awareness spreads.

Supply chain capacity has become a significant factor limiting growth, with multiple manufacturers and compounding pharmacies struggling to meet demand throughout 2023 and into 2024. This supply constraint has inadvertently created a favorable environment for licensed 503A compounding pharmacies, which offer alternative formulations and personalized dosing protocols that match individual patient metabolism and genetic predisposition. PlexusDx serves all 50 states with compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan, removing geographic and insurance limitations that previously restricted access.

Why GLP-1 Drug Usage Has Increased So Rapidly

Three primary drivers explain the explosive growth in GLP-1 medication adoption over the past 24-36 months. First, landmark clinical trials published between 2021-2023 demonstrated sustained weight loss of 15-22% over 68 weeks in patients taking semaglutide or tirzepatide, substantially outperforming previous pharmaceutical options and behavioral interventions alone. Second, cardiovascular safety data showed that GLP-1 therapy reduced major adverse cardiac events in both diabetic and non-diabetic populations, expanding the therapeutic rationale beyond weight loss into preventive cardiology.

Third, media attention and influencer endorsements dramatically increased public awareness of GLP-1 effectiveness, creating patient demand that pressured healthcare systems to expand access. Insurance coverage expanded accordingly, though formulary restrictions and prior authorization requirements still limit immediate access for many patients. Compounded GLP-1 options bypass these insurance barriers entirely, allowing patients to start therapy within days rather than weeks or months, which has contributed substantially to direct-to-consumer adoption rates.

Understanding Individual Response and Genetic Factors in GLP-1 Treatment

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437) and FTO (rs9939609) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

This precision-medicine framework transforms GLP-1 treatment from a one-size-fits-all prescription into a personalized protocol matched to each patient's biochemical profile. PlexusDx adds the Precision Peptide Genetic Test for $298, enabling patients and clinicians to optimize medication selection, dosing strategy, and combination therapy based on measurable genetic predispositions rather than trial-and-error escalation. This approach often reduces side effects, accelerates weight loss timelines, and improves long-term treatment adherence by matching therapy to individual physiologic capacity.

Compounded vs. Brand-Name GLP-1 Options in Today's Market

The distinction between brand-name GLP-1 medications and licensed 503A compounded formulations has become increasingly important as patients navigate cost, access, and availability constraints. Brand-name semaglutide (Ozempic, Wegovy) carries retail prices ranging from $900-$1,500 per month without insurance, while brand-name tirzepatide (Mounjaro, Zepbound) costs $1,000-$1,600 monthly, creating prohibitive barriers for many patients despite clinical eligibility. Licensed 503A compounding pharmacies can manufacture chemically identical semaglutide and tirzepatide at substantially lower cost by sourcing bulk active pharmaceutical ingredients and eliminating manufacturer marketing expenses.

PlexusDx provides compounded semaglutide injections from licensed 503A compounding pharmacies at $189/mo month-to-month, or from $149/mo on the 6-month plan flat—no price increases as dose escalates—making treatment accessible nationwide without insurance requirements or membership fees. Patients can also access oral semaglutide at $289/mo (or $249/mo on the 6-month plan), compounded tirzepatide injections at $289/mo month-to-month, or from $249/mo on the 6-month plan, or the GLP-Squared dual-compound formula blending both agents at $289 monthly for injections. All formulations remain HSA and FSA eligible, and no prior authorization or insurance approval delays access to therapy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What percentage of the U.S. population is currently using GLP-1 medications?

Approximately 3-4% of the total U.S. population has filled a GLP-1 prescription, representing roughly 9-15 million individuals across diabetes, weight loss, and cardiovascular indication categories.

Does GLP-1 therapy produce better weight loss results than diet and exercise alone?

Clinical trials demonstrate that GLP-1 medications produce 15-22% weight reduction over 68 weeks compared to 2-3% reduction with behavioral intervention alone, representing a 7-10 fold improvement in weight loss efficacy.

How much does GLP-1 treatment cost through PlexusDx, and do I need insurance?

PlexusDx provides compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan flat with flat pricing — your dose may go up, but your price won't. No insurance is required, and all formulations are HSA and FSA eligible, making treatment accessible within days of consultation regardless of insurance status or prior authorization delays.

Are compounded GLP-1 medications as safe and effective as brand-name versions?

Compounded GLP-1 medications from licensed 503A compounding pharmacies contain chemically identical active pharmaceutical ingredients as brand-name formulations, delivering equivalent clinical efficacy and safety profiles.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes—PlexusDx offers the Precision Peptide Genetic Test for $298, analyzing 14 peptide pathways and 150+ genetic insights including GIPR variants that influence individual medication response.

Related Reading

• History Of Glp 1 Drugs Plexusdx
• Glp 1 Agonist Drugs
• Glp 1 Drugs List
• Drugs Glp 1

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.